Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-03-26
2009-12-29
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000, C530S387100, C530S387300, C435S069100, C435S325000, C514S012200
Reexamination Certificate
active
07638480
ABSTRACT:
The invention relates to the use of osteoprotegerin for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4737462 (1988-04-01), Mark et al.
patent: 4879111 (1989-11-01), Chong
patent: 4904584 (1990-02-01), Shaw
patent: 4959314 (1990-09-01), Mark et al.
patent: 4965195 (1990-10-01), Namen et al.
patent: 5017691 (1991-05-01), Lee et al.
patent: 5116943 (1992-05-01), Koths et al.
patent: 7005413 (2006-02-01), Boyle et al.
patent: 2005/0143301 (2005-06-01), Power et al.
patent: 2006/0019887 (2006-01-01), Dunstan
patent: 2006/0084595 (2006-04-01), Yamamoto et al.
patent: WO 92/13095 (1992-08-01), None
patent: WO 98/35043 (1998-08-01), None
patent: WO 99/53942 (1999-10-01), None
patent: WO 01/17543 (2001-03-01), None
patent: WO 02/46225 (2002-06-01), None
Franklin. Current approaches to the therapy of fibrotic diseases. Biochemical Pharmacology. vol. 49, No. 3, pp. 267-273 (1995).
Sato et al. Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common B subunit responsible for different signaling. The EMBO Journal, vol. 12, No. 11, pp. 4181-4189 (1993).
Krane , S. M., “Is Collagenase (Matrix Metalloproteinase-1) Necessary for Bone and Other Connective Tissue Remodeling?” Clinical Orthopaedics and Related Research, vol. 313, pp. 47-53 (1995).
Takehara et al., “Localized scleroderma is an autoimmune disorder,” Rheumatology, 44:274-279 (2005).
Wells, James A., “Additivity of Mutational Effects in Proteins,” Biochemistry, 29(37):8509-8517 (1990).
Abraham et al., “Expression and function of surface antigens on scleroderma fibroblasts,” Arthritis Rheum, 34:1164-1172 (1991).
Bucay et al., “Osteoprotegerin-deficient mice develop early onset osteorporosis and arterial calcification,” Genes & Development, 12:1260-1268 (1998).
Granot et al., “Halofuginone: an inhibitor of collagen type I synthesis,” Biochimica Biophys. Acta 1156:107-112 (1993).
Hattori et al., “Bleomycin induced pulmonary fibrosis in fibrinogen null mice,” J. Clin. Invest. 106:1341-1350 (2000).
Heron et al., “Intracerebral Calcification in Systemic Sclerosis,” Stroke, 30(10):2183-2185 (1999).
Kostenuik et al., “Osteoprotegerin: A Physiological and Pharmacological Inhibitor of Bone Resorption,” Curr. Pharm Des, 7(8):613-635 (2001).
Leighton, “Drug Treatment of Scleroderma,” Drugs 61(3):419-427 (2001).
Malyankar et al., “Osteoprotegerin is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells,” Journal of Biological Chem., 275(28):20959-20962 (2000).
Martini et al., “Marked and Sustained Improvement Two Years After Autologous Stem Cell Transplantation in a Girl With Systemic Sclerosis,” Arthritis Rheum. 42:807-811 (1999).
Mathiesen et al., “The Clinical Significance of Slightly to Moderately Increased Liver Transaminase Values in Asymptomatic Patients,” Scand J Gastroenterol., 34(1):85-91 (1999).
McGaha et al., “Halofuginone, an Inhibitor of Type-1 Collagen Synthesis and Skin Sclerosis, Blocks Transforming Growth-Factor-β-Mediated Smad3 Activation in Fibroblasts,” J. Invest Derm., 118:461-470 (2002).
Min et al., “Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis,” J. Exp. Med., 192:463-474 (2000).
Morinaga et al., “Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor,” Eur. J. Biochem., 254:685-691 (1998).
Salant, et al., “Heymann nephritis: Mechanisms of renal injury,” Kidney Int. 35:976-984 (1989).
Shi-wen et al., “Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis,” Arthritis Rheum, 40:1237-1244 (1997).
Simonet et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” Cell, 89:309-319 (1997).
Smith et al., “Production and function of murine macrophage inflammatory protein-1α in bleomycin-induced lung injury,” J. Immunol., 153:4704-4712 (1994).
Wigley et al., “Novel therapy in the treatment of scleroderma,” Exp. Opin. Invest. Drugs, 10(1):31-48 (2001).
Wigley et al., “The treatment of scleroderma,” Curr. Opin. In Anti-inflam. & Immun. Invest. Drugs, 2:276-292 (2000).
Yano et al., “Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor,” J. Bone Miner Metab., 19:365-372 (2001).
Yasuda et al., “Identity of osteoclastogenesisis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro,” Endocrinology, 139:1329-1337 (1998).
Disthabanchong et al, “Regulation of bne cell development and function: implications from renal osteodystrophy”, Journal of Investigative medicine. vol. 49, pp. 5117-5123, 1998.
Varga et al, “Systemic sclerosis: a prototypic multisystem fibrotic disorder”, The Journal of Clinical Investigation, vol. 117, No. 3, pp. 557-567, 2003.
Wynn, “Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases”, The Journal of Clinical Investigation, vol. 117, No. 3, pp. 524-529, 2007.
Wynn, “Fibrotic disease and the Th1/Th2 paradigm” Nature Reviews Immunology. vol. 4, No. 8, pp. 583-594 (2004).
Yamaguchi et al, “Characterization of structural domains of himan osteoclastogenesis inhibitory factor”, The Journal of Biological Chemistry, vol. 273, No. 9, pp. 5117-5123, 1998.
Auerbach, R., “Angiogenesis Assays: Problems and Pitfalls”, Cancer and Metastasis Review, 19: pp. 167-172, 2000.
Berendsen, HJC, “A Glimpse of the Holy Grail”, Science, 282: 642-643, 1998.
Gura T., “Cancer Models: Systems for Identifying New Drugs Are Often Faulty”, Science, 278(5340): 1041-1042, enclosed pp. 1-6, 1997.
Jain, RK., “Barriers to Drug Delivery in Solid Tumors”, Scientific American, pp. 58-65, 1994.
Rudinger, J. “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence”, JA Parsons Ed., pp. 1-7, 1976.
Voet and Voet, “Biochemistry”, Second Edition, John Wiley & Sons, Inc., pp. 235-241, 1995.
Beasley, DJ, et al., “Fibro-osseous lesions of the head and neck”, The Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society, vol. 148(10), pp. 413-415, 1996.
Brown et al., “Fibrous Dysplasia of the Temporal Bone: Imaging Findings”, Abstract, American Journal of Roentgenology, vol. 164, No. 3, pp. 679-682, 1995.
Lane et al., “Bisphosphonate Therapy in Fibrous Dysplasia”, Abstract, Clinical Orthopaedics and Related Research, No. 382, pp. 6-12, 2001.
Mohammadi-Araghi et al., “Fibro-osseous Lesions of Craniofacial Bones”, Abstract, The Role of Imaging. Radiologic Clinics of North America, vol. 13, No. 1, pp. 121-134, 1993.
Rosenblum et al., “Monostotic Fibrous Dysplasia of the Thoracic Spine”, Abstract, Spine, vol. 12, No. 9, pp. 939-942, 1987.
Plater-Zyberk Christine
Power Christine
DeBerry Regina M
Laboratoires Serono SA
Ropes & Gray LLP
Saoud Christine J
LandOfFree
Use of osteoprotegerin for the treatment and/or prevention... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of osteoprotegerin for the treatment and/or prevention..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of osteoprotegerin for the treatment and/or prevention... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078894